- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2162-3619
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Immune pressures drive the promoter hypermethylation of neoantigen genes ; volume:8 ; number:1 ; day:29 ; month:11 ; year:2019 ; pages:1-3 ; date:12.2019
Experimental hematology & oncology ; 8, Heft 1 (29.11.2019), 1-3, 12.2019
- Urheber
-
Yi, Ming
Dong, Bing
Chu, Qian
Wu, Kongming
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40164-019-0156-7
- URN
-
urn:nbn:de:101:1-2020032618452141905893
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:46 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Yi, Ming
- Dong, Bing
- Chu, Qian
- Wu, Kongming
- SpringerLink (Online service)
Ähnliche Objekte (12)
Frequent RASSF1A gene promoter hypermethylation in breast cancer
SIP1 is downregulated in hepatocellular carcinoma by promoter hypermethylation
Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma
The role of neoantigen in immune checkpoint blockade therapy
Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation
TMEFF2 promoter hypermethylation is an unfavorable prognostic marker in gliomas
Pervasive promoter hypermethylation of silenced TERT alleles in human cancers
CHD5 is down-regulated through promoter hypermethylation in gastric cancer
TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer
SLIT2 promoter hypermethylation predicts disease progression in chronic myeloid leukemia
PER3 promoter hypermethylation correlates to the progression of pan-cancer
Cyclin A1 promoter hypermethylation in human papillomavirus-associated cervical cancer
Frequent RASSF1A gene promoter hypermethylation in breast cancer
SIP1 is downregulated in hepatocellular carcinoma by promoter hypermethylation
Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma
The role of neoantigen in immune checkpoint blockade therapy
Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation
TMEFF2 promoter hypermethylation is an unfavorable prognostic marker in gliomas
Pervasive promoter hypermethylation of silenced TERT alleles in human cancers
CHD5 is down-regulated through promoter hypermethylation in gastric cancer
TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer
SLIT2 promoter hypermethylation predicts disease progression in chronic myeloid leukemia
PER3 promoter hypermethylation correlates to the progression of pan-cancer
Cyclin A1 promoter hypermethylation in human papillomavirus-associated cervical cancer
Frequent RASSF1A gene promoter hypermethylation in breast cancer
SIP1 is downregulated in hepatocellular carcinoma by promoter hypermethylation
Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma
The role of neoantigen in immune checkpoint blockade therapy
Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation
TMEFF2 promoter hypermethylation is an unfavorable prognostic marker in gliomas
Pervasive promoter hypermethylation of silenced TERT alleles in human cancers
CHD5 is down-regulated through promoter hypermethylation in gastric cancer
TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer
SLIT2 promoter hypermethylation predicts disease progression in chronic myeloid leukemia
PER3 promoter hypermethylation correlates to the progression of pan-cancer